Key result
Recombinant human soluble thrombomodulin therapy resulted in marked clinical and laboratory improvement in a patient with a homozygous Gly412Asp thrombomodulin mutation.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This first reported case of hereditary functional thrombomodulin deficiency demonstrates that recombinant human soluble thrombomodulin therapy can yield marked clinical and laboratory improvement.
Thrombomodulin functions as an anticoagulant through thrombin binding and protein C activation. We herein report the first case of hereditary functional thrombomodulin deficiency presenting with recurrent subcutaneous hemorrhage and old cerebral infarction. The patient had a homozygous substitution of glycine by aspartate at amino acid residue 412 (Gly412Asp) in the thrombin-binding domain of the thrombomodulin gene (designated thrombomodulin-Nagasaki). In vitro assays using a recombinant thrombomodulin with the same mutation as the patient showed a total lack of thrombin binding and activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI). Marked clinical and laboratory improvement was obtained with recombinant human soluble thrombomodulin therapy.
No takes yet. Share an insight, caveat, or question.
Okada et al. (2020) conducted a case report in Hereditary functional thrombomodulin deficiency (n=1). Recombinant human soluble thrombomodulin therapy was evaluated on Clinical and laboratory improvement. Recombinant human soluble thrombomodulin therapy resulted in marked clinical and laboratory improvement in a patient with a homozygous Gly412Asp thrombomodulin mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: